Mediland Pharm Limited reported preliminary audited consolidated and parent earnings results for the year ended June 30, 2019. For the period, on consolidated basis, the company reported revenue of AUD 30,661,259 against AUD 34,083,675 a year ago. Loss after income tax expense for the year attributable to the owners of the company was AUD 11,244 or 0.01 cents per basic share against profit of AUD 3,428,033 or 1.87 cents per basic share a year ago. For the period, on parent basis, the company reported profit for the year of AUD 676,748 against loss of AUD 177,427 a year ago.